Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer

Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.

Detalles Bibliográficos
Autor principal: Jacobson, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Conference Perspectives: Highlights from SABCS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963159/
https://www.ncbi.nlm.nih.gov/pubmed/35348782
http://dx.doi.org/10.1093/oncolo/oyac011
_version_ 1784677931854856192
author Jacobson, Anne
author_facet Jacobson, Anne
author_sort Jacobson, Anne
collection PubMed
description Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial.
format Online
Article
Text
id pubmed-8963159
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-89631592022-03-29 Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer Jacobson, Anne Oncologist Conference Perspectives: Highlights from SABCS Alpelisib and endocrine therapy provides ongoing treatment benefits for patients with HR-positive, HER2-negative, PIK3CA-mutated advanced breast cancer, according to updated findings from all 3 cohorts of the phase II BYLieve trial. Oxford University Press 2022-03-28 /pmc/articles/PMC8963159/ /pubmed/35348782 http://dx.doi.org/10.1093/oncolo/oyac011 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Conference Perspectives: Highlights from SABCS
Jacobson, Anne
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
title Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
title_full Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
title_fullStr Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
title_full_unstemmed Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
title_short Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
title_sort alpelisib plus fulvestrant or letrozole demonstrates sustained benefits across subgroups of patients with pik3ca-mutated hr+/her2– advanced breast cancer
topic Conference Perspectives: Highlights from SABCS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963159/
https://www.ncbi.nlm.nih.gov/pubmed/35348782
http://dx.doi.org/10.1093/oncolo/oyac011
work_keys_str_mv AT jacobsonanne alpelisibplusfulvestrantorletrozoledemonstratessustainedbenefitsacrosssubgroupsofpatientswithpik3camutatedhrher2advancedbreastcancer

Ejemplares similares